Three pieces of legislation introduced by U.S. Rep. Bob Latta (R-OH) that aim to help fight the nation’s opioid epidemic received approval on Tuesday from the U.S. House Energy and Commerce Committee. The committee approved the Strengthening Tools to Outlaw Poisonous (STOP) Nitazenes Act, H.R. 7970, which Rep. Latta sponsored on March 18, would schedule 2-benzylbenzimidazole opioids, commonly known as nitazenes, as Schedule I controlled substances because they are increasingly contributing to overdose deaths nationwide. Additionally, the House Energy and Commerce Committee passed the bipartisan Nonprescription Drug Innovation Act, H.R. 9774, as part of the larger Lower Costs, More Transparency Act, H.R.